tiprankstipranks
Trending News
More News >
Tissue Regenix Group PLC (GB:TRX)
LSE:TRX
Advertisement

Tissue Regenix (TRX) Stock Statistics & Valuation Metrics

Compare
14 Followers

Total Valuation

Tissue Regenix has a market cap or net worth of £26.36M. The enterprise value is 33.41M.
Market Cap£26.36M
Enterprise Value33.41M

Share Statistics

Tissue Regenix has 71,395,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,395,640
Owned by Insiders
Owned by Institutions

Financial Efficiency

Tissue Regenix’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.33%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)1.33%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee349.34K
Profits Per Employee-4.78K
Employee Count82
Asset Turnover0.63
Inventory Turnover1.07

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF-4.35
Price to Operating Cash Flow0.00
PEG Ratio0.00

Income Statement

In the last 12 months, Tissue Regenix had revenue of 28.65M and earned -713.00K in profits. Earnings per share was 0.00.
Revenue28.65M
Gross Profit13.62M
Operating Income349.00K
Pretax Income-564.00K
Net Income-713.00K
EBITDA1.36M
Earnings Per Share (EPS)0.00

Cash Flow

In the last 12 months, operating cash flow was -1.33K and capital expenditures -360.11K, giving a free cash flow of -361.44K billion.
Operating Cash Flow-1.33K
Free Cash Flow-361.44K
Free Cash Flow per Share>-0.01

Dividends & Yields

Tissue Regenix pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.17
52-Week Price Change-44.70%
50-Day Moving Average31.36
200-Day Moving Average45.12
Relative Strength Index (RSI)65.52
Average Volume (3m)112.16K

Important Dates

Tissue Regenix upcoming earnings date is Sep 3, 2025, TBA (Confirmed).
Last Earnings DateJun 25, 2025
Next Earnings DateSep 3, 2025
Ex-Dividend Date

Financial Position

Tissue Regenix as a current ratio of 3.46, with Debt / Equity ratio of 35.10%
Current Ratio3.46
Quick Ratio1.18
Debt to Market Cap0.00
Net Debt to EBITDA6.30
Interest Coverage Ratio0.40

Taxes

In the past 12 months, Tissue Regenix has paid 289.00K in taxes.
Income Tax289.00K
Effective Tax Rate-0.51

Enterprise Valuation

Tissue Regenix EV to EBITDA ratio is 6.30, with an EV/FCF ratio of -1.51.
EV to Sales0.30
EV to EBITDA6.30
EV to Free Cash Flow-1.51
EV to Operating Cash Flow-5.26

Balance Sheet

Tissue Regenix has £3.46M in cash and marketable securities with $10.47M in debt, giving a net cash position of £7.01M billion.
Cash & Marketable Securities£3.46M
Total Debt$10.47M
Net Cash£7.01M
Net Cash Per Share£0.10
Tangible Book Value Per Share£0.00

Margins

Gross margin is 47.55%, with operating margin of 1.22%, and net profit margin of -2.49%.
Gross Margin47.55%
Operating Margin1.22%
Pretax Margin-1.97%
Net Profit Margin-2.49%
EBITDA Margin4.76%
EBIT Margin1.11%

Analyst Forecast

The average price target for Tissue Regenix is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-5.33%
EPS Growth Forecast60.20%

Scores

Smart Score2
AI Score66.5
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis